Market Cap (In CNY)
22.89 Billion
Revenue (In CNY)
2.45 Billion
Net Income (In CNY)
348.03 Million
Avg. Volume
8.12 Million
- Currency
- CNY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 30.43-59.0
- PE
- -
- EPS
- -
- Beta Value
- 0.759
- ISIN
- CNE100002DD9
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Dr. Lieming Ding
- Employee Count
- -
- Website
- https://www.bettapharma.com
- Ipo Date
- 2016-11-09
- Details
- Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.
More Stocks
-
ABI
-
BNRE
-
HAZOOR
-
688309
-
BGRDF
-
LAOPALALa Opala RG Limited
LAOPALA
-
0HVF
-
PRIC-BPricer AB (publ)
PRIC-B